Pulmonary interstitial lymphography: A prospective trial with potential impact on stereotactic ablative radiotherapy planning for early-stage lung cancer

Stereotactic ablative radiotherapy (SABR) is the standard of care for medically inoperable early-stage non-small cell lung cancer (NSCLC). Extensive evidence demonstrates that SABR is efficacious with low toxicity [1 –2], and an important question is the potential role of SABR in the medically operable setting [3–6]. Several randomized trials comparing SABR to surgical resection continue to accrue (e.g., NCT02468024, NCT02984761, NCT01753414) and preliminary comparisons of SABR vs. lobectomy for early-stage NSCLC indicate that survival is similar and SABR is associated with significantly fewer side effects [3,6].

Source: Radiotherapy and Oncology - December 30, 2023 Category: Radiology Authors: Ryan B. Ko, Jonathan A. Abelson, Dominik Fleischmann, John D. Louie, Gloria L. Hwang, Daniel Y. Sze, Emil Sch üler, Kayla N. Kielar, Peter G. Maxim, Quynh-Thu Le, Wendy H. Hara, Maximilian Diehn, Nishita Kothary, Billy W. Loo Tags: Short Communication Source Type: research